Uniti Group Inc. Reports Fourth Quarter and Full Year 2025 Results

Ingram Micro Q4 Earnings Call Highlights

Ingram Micro (NYSE:INGM) executives said the company closed fiscal 2025 with results above the high end of its guidance, citing broad-based regional growth, continued strength in enterprise demand, and a sharp increase in quarterly free cash flow driven by working capital reductions and operational

Uniti Reports $305M Q4 Loss, Full-Year Income of $1.3B

Uniti Group Inc. (Nasdaq: UNIT) of Little Rock on Monday reported a $305.7 million loss for the fourth quarter of 2025, down from $21.6 million in profit in the same quarter of 2024. The three-month period ending Dec. 31 was the second full quarter of operations for the company following the completion of its $13.4 billion merger with Windstream in August. Per share, the loss came out to $1.19. The loss was largely driven by merger-related expen…

Uniti (UNIT) Q4 2025 Earnings Call Transcript

Open the article to view the coverage from The Motley Fool

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic...

Uniti: Q4 Earnings Snapshot

LITTLE ROCK, Ark. (AP) — LITTLE ROCK, Ark. (AP) — Uniti Group Inc. (UNIT) on Monday reported a loss of $305.7 million in its fourth quarter.

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 ...

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J…